Evidence map›Paper›PMID 17913806›Full record

ArticleJournal of virology2007

Mapping protease inhibitor resistance to human immunodeficiency virus type 1 sequence polymorphisms within patients.

Art F Y Poon, Sergei L Kosakovsky Pond, Douglas D Richman, Simon D W Frost

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Methodologies for Microbial Ancestral Sequence Reconstruction.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Genetic Consequences of Antiviral Therapy on HIV-1.Computational and mathematical methods in medicine · 2015
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Art F Y PoonDepartment of Pathology, University of California, San Diego, La Jolla, California, USA. afpoon@ucsd.edu
Sergei L Kosakovsky Pond
Douglas D Richman
Simon D W Frost
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Southern California Primary Infection ProgramU01AI043638 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 1998 to 2010
$21.3M
Biomathematical analysis of viral dynamics/evolutionR01AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RICHMAN, DOUGLAS D · 2001 to 2011
$3.2M
Modeling HIV Escape from Neutralizing Antibody ResponesR01AI057167 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FROST, SIMON DAVID WILLIAM · 2004 to 2008
$1.2M
Biomathematical Analysis of Viral Dynamics and EvolutionR56AI047745 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POND, SERGEI L KOSAKOVSKY · 2012 to 2012
$365k
BIOMATHEMATICAL ANALYSIS OF VIRAL DYNAMICS AND EVOLUTIONR21AI047745 · NIAID · UNIVERSITY OF CALIFORNIA SAN DIEGO · PI RICHMAN, DOUGLAS D · 2000 to 2000
$308k
NIAID NIH HHS AI36214NIAID NIH HHS AI43638NIAID NIH HHS AI47745NIAID NIH HHS AI57167NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI047745NIAID NIH HHS R01 AI057167NIAID NIH HHS R21 AI047745NIAID NIH HHS R56 AI047745NIAID NIH HHS U01 AI043638
6 · The paper itself

Abstract

Resistance genotyping provides an important resource for the clinical management of patients infected with human immunodeficiency virus type 1 (HIV-1). However, resistance to protease (PR) inhibitors (PIs) is a complex phenotype shaped by interactions among nearly half of the residues in HIV-1 PR. Previous studies of the genetic basis of PI resistance focused on fixed substitutions among populations of HIV-1, i.e., host-specific adaptations. Consequently, they are susceptible to a high false discovery rate due to founder effects. Here, we employ sequencing "mixtures" (i.e., ambiguous base calls) as a site-specific marker of genetic variation within patients that is independent of the phylogeny. We demonstrate that the transient response to selection by PIs is manifested as an excess of nonsynonymous mixtures. Using a sample of 5,651 PR sequences isolated from both PI-naive and -treated patients, we analyze the joint distribution of mixtures and eight PIs as a Bayesian network, which distinguishes residue-residue interactions from direct associations with PIs. We find that selection for resistance is associated with the emergence of nonsynonymous mixtures in two distinct groups of codon sites clustered along the substrate cleft and distal regions of PR, respectively. Within-patient evolution at several positions is independent of PIs, including those formerly postulated to be involved in resistance. These positions are under strong positive selection in the PI-naive patient population, implying that other factors can produce spurious associations with resistance, e.g., mutational escape from the immune response.

Indexed as

Polymorphism, GeneticBayes TheoremDrug Resistance, ViralEvolution, MolecularGenetic VariationHIV-1HIV InfectionsHIV ProteaseHIV Protease InhibitorsHumansMarkov ChainsModels, MolecularMonte Carlo MethodHIV ProteaseHIV Protease Inhibitors

Identifiers

PMID17913806
PMCPMC2168824
OpenAlexW2129465264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.